Navigation Links
Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
Date:7/10/2008

Expands Focus to Include Intelligent Devices in Treatment of Heart Failure

and Cardiovascular Diseases

SUNRISE, Fla., July 10 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT), a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases, today announced it has secured worldwide non-exclusive distribution rights to the Bioheart 3370 Heart Failure Monitor, an interactive and simple-to-use at-home intelligent device designed specifically to improve available healthcare to patients outside hospitals who are suffering from heart failure. The device, manufactured by RTX Healthcare A/S (Denmark), has 510k market clearance from the US Food and Drug Administration for marketing in the U.S. and CE mark approval for marketing in Europe and other countries that follow this mark. The Company is planning to begin immediate commercial distribution.

The compact Bioheart 3370 Heart Failure Monitor engages patients through personalized daily interactions and questions, while collecting vital signs and transmitting the information directly into a database. It is uniquely available in both a wireless configuration and through hook-up to regular telephone lines. The data are regularly monitored by a remotely located medical professional, who watches for any abnormal readings that may signal a change in the patient's health status. These changes are reported back to the treating physician.

"Remote monitoring of heart failure patients forms a cornerstone of heart failure disease management, enhancing the opportunity to avoid episodes of worsening heart failure and emergency hospitalizations," said William Abraham, MD, profess
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
2. Bioheart, Inc., Added to Russell Microcap Index
3. Bioheart, Inc. to Transfer to Nasdaq Capital Market
4. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
5. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
6. Bioheart, Inc. Announces Financial Results for First Quarter 2008
7. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
8. Liko Introduces Two Additions to Its Stat Family of Low Friction Sheets
9. Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R)
10. Berkley Life Sciences Introduces LS Prime: A Revolutionary New Primary Liability Policy for the Life Science Industry
11. Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open ... the pain management and clinical markets. The software increases ... by allowing users to highlight and review results that ... allows analysts to filter results by group or based ... eliminating the need to sift through analytes of no ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... , , BASKING RIDGE, N.J., Sept. 3 ... of antithrombotic aptamers with active control agents, announced today that ... be presenting at the 11th Annual Healthcare Conference of the ... at 4:30 PM on Thursday, September 10, 2009 (EDT). ...
... , ANNAPOLIS, Md., Sept. 3 PharmAthene, ... developing medical countermeasures against biological and chemical threats, announced today ... (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program ... 30 - September 3, 2009, organized by the American Society ...
... Global ... , ... September 3, 2009 -- Global animal health company, Alltech was featured as one ... and selling natural animal feed supplements with their 2008 revenues exceeding $400,000,000. It is ...
Cached Biology Technology:Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009 2PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 2PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 3PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 4PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 5PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 6PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 7PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 8PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 9Alltech Breaks Through: Named Top Green Company by Inc. Magazine 2
(Date:10/18/2014)... of 2,000 patients referred for evaluation of suspected ... diagnosis for 25 percent, including detection of a ... contributing to disease, according to a study appearing ... released to coincide with the American Society of ... the exons or coding regions of thousands of ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... mushroom (Agaricus bisporus) has as much, and in some cases, ... button mushroom is the foremost cultivated edible mushroom in the ... is often thought of as a poor relation to its ... nutritionally. But according to new research in SCIs Journal ...
... Fan Meng of China, a visionary leader who ... in Chinas rapidly industrializing Guangdong Province, has been awarded ... use the Fellowship to expand and improve the regions ... from the serious threats of industrial pollution and unsustainable ...
... to distinguish between the majority of plant species on Earth ... the Proceedings of the National Academy of Sciences journal today ... used to identify plants using a small sample, could lead ... in species-rich areas like rainforests. It could also lead to ...
Cached Biology News:2008 Pew Fellowship in Marine Conservation awarded to Fan Meng; first Chinese fellow 22008 Pew Fellowship in Marine Conservation awarded to Fan Meng; first Chinese fellow 3DNA 'barcode' identified for plants 2DNA 'barcode' identified for plants 3
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: